The Potential of Candesartan to Retard the Progression of Aortic Stenosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The present study defines a blinded, randomized, placebo-controlled, prospective study, the aim of which is to determine the influence of effective treatment with Type 1 angiotensin II (Ang II) receptor (AT-1R) antagonist, using candesartan (target dose 16 mg) on stenotic aortic valves. The investigators will specifically quantify whether candesartan attenuates the key pathogenic mechanisms of aortic valve stenosis, namely inflammation, fibrosis, elastin degradation, calcification, and neovascularization.
Epistemonikos ID: bbefcf4dde201bb5433be5dc54d90dcd8773b0c2
First added on: May 05, 2024